Updated on 5 September 2026
Human Stem Cell-Derived Cardiovascular Safety Testing
About
ABS is a pioneering biotechnology company specializing in human stem cell-derived cardiovascular models for predictive drug safety assessment and translational research.
Our platform enables pharmaceutical, biotechnology, and regenerative medicine companies to evaluate cardiac safety earlier and more accurately using human-relevant biology, helping to reduce development risk and improve decision-making throughout the drug development process.
We are seeking partnerships with organizations interested in:
-
Drug safety and cardiotoxicity assessment
-
Cardiovascular disease modeling
-
Translational and preclinical research
-
Regenerative medicine and cell therapy development
-
Co-development and joint research projects
-
Technology licensing and strategic collaborations
At the EU-Japan Biotech & Pharma Partnering event, we are particularly interested in connecting with Japanese and European companies looking to accelerate innovation in cardiovascular medicine through advanced human stem cell-derived technologies.
We welcome discussions with pharmaceutical companies, biotech innovators, CROs, academic institutions, and regenerative medicine organizations seeking reliable, human-relevant solutions for cardiovascular research and drug development.
Type
- Development
- Manufacturing
Applies to
- Biotech and Lifescience
Similar opportunities
Service
Translational Experimental Surgery: Multi-System Disease Models from Mouse to Swine
- Consulting
- Development
- Biotech and Lifescience
Service
- Medtech
- Consulting
- Biotech and Lifescience